Expression and Clinical Significance of Antiapoptotic Gene (Survivin)‎ in NB4 and Acute Promyelocytic Leukemia Cells

Abstract EN

To study survivin gene expression in APL cells and to explore its correlation with clinical manifestations.

PML/RARα and survivin mRNA expression were analysed using RT-PCR.

By treatment of ATRA, the survivin mRNA expression in NB4 cells gradually decreased with time and was almost undetectable in the 72th hour.

Survivin was expressed in 67% of the 36 APL cases (de novo and relapse patients) with PML/RARα fusion gene expression.

However, in 22 cases of remission stage patients without PML/RARα fusion gene expression, survivin was expressed in 36%.

The survivin mRNA expression positive rate in de novo and relapse groups, and PML/RARα fusion gene L-type positive groups, was obviously higher than those in remission period groups and was significantly lower than those in acute leukemia groups.

In 36 cases of de novo and relapse APL patients, all cases could obtain complete remission, irrespective of the survivin expression.

APL patients expressed with survivin mRNA had DIC and serious infection (one patient died).

The clinical symptom included slight skin or mucosa bleeding, fever, and asthenic for patients without the survivin mRNA expression.

Later, two cases of APL patients with the survivin mRNA expression were treated by ATRA, induction differentiation sign in their peripheral blood and bone marrow figure was not obvious.

It was concluded that the survive gene expression was lower in APL than those in any other types of leukemia, thus closely associated with clinical manifestation.